Eloxatin Adjuvant Indication Could Nearly Double Sanofi’s Target Market
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Sanofi-Synthelabo’s pending NDA for use of Eloxatin in the adjuvant colorectal cancer setting could roughly double the potential patient population for the oncologic.